Eton Pharmaceuticals, Inc. ETON R2K
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
READ MORE ›$30.45
+61.20% 1Y
Market & Price
Market Cap
$834.10M
Current Price
$30.45
High / Low (52W)
$35.00 / $13.50
Beta
0.82
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
16.20
PEG Ratio
-
Book Value
$0.97
Price to Book
31.49
P/S
9.59
EV/EBITDA
76.29
Dividend Yield
-
Profitability & Returns
ROCE
-1.57%
ROE
-5.36%
ROA
4.76%
Profit Margin
-1.70%
Op Margin
11.39%
EPS (Latest Qtr)
$0.05
EPS (TTM)
$-0.06
Balance Sheet & Liquidity
Debt/Equity
1.02
Quick Ratio
0.75
Current Ratio
1.21
Debt
$31.26M
Total Assets
$92.11M
Current Assets
$60.58M
Working Capital
$22.09M
Ownership
Promoter Holding
4.89%
Chg in Prom Hold
-
FII / Inst Holding
65.40%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$845.70M
Total Revenue (TTM)
$86.93M
EBITDA
$11.09M
Free Cash Flow
$2.44M
Operating Cash Flow
$15.84M
Shares Outstanding
27.39M
Gross Margin
59.72%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
55.53%
Profit 5Y
16.33%
Revenue (YoY)
40.40%
Earnings (YoY)
-
PROS
- Compounding revenue at 55.5% over 5 years.
- Profit CAGR of 16.3% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ETON Eton Pharmaceuticals, Inc. R2K | 30.45 | - | $834.10M | - | -1.57% | -5.36% | 55.53% | 16.33% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 500.00K | - | - | 459.00K | 99.00K | 20.00K | -161.00K | 11.90M | 3.07M | 775.00K | 2.18M | 7.36M | 3.22M | 5.30M | 12.00M | 7.03M | 7.97M | 9.07M | - | 17.28M | 18.93M | 22.46M | 21.28M | 24.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.42M | 7.00M | 14.60M | 8.18M | 9.53M |
| Gross Profit | - | - | - | - | - | 500.00K | - | - | - | -3.00K | -8.00K | -17.00K | 10.31M | 2.89M | 121.00K | 1.33M | 4.61M | 2.02M | 3.35M | 9.68M | 4.40M | 5.01M | 5.63M | - | 9.86M | 11.92M | 7.86M | 13.10M | 14.73M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.33M | 13.40M | 9.22M | 10.64M | 12.32M |
| Operating Income | -2.77M | -2.96M | -2.70M | -2.37M | - | -7.55M | -3.35M | -5.04M | - | -8.88M | -4.54M | -6.27M | 5.36M | -2.33M | -5.85M | -5.09M | -1.34M | -2.90M | -2.53M | 3.88M | -548.00K | -800.00K | -2.94M | - | -470.00K | -1.48M | -1.36M | 2.46M | 2.41M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 543.00K | -470.00K | -354.00K | 3.48M | 3.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.00K | 1.03M | 1.04M | 592.00K | - | 840.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.50M | -2.52M | -1.96M | 1.41M | 1.57M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.00K | 66.00K | -28.00K | -69.00K | 20.00K |
| Net Income | -2.80M | -3.02M | -3.08M | -2.91M | -3.73M | -7.41M | -3.25M | -4.96M | -2.70M | -9.05M | -4.73M | -6.50M | 5.12M | -2.02M | -6.09M | -5.33M | -1.56M | -3.04M | -2.66M | 4.56M | -579.00K | -811.00K | -3.04M | - | -1.57M | -2.58M | -1.93M | 1.48M | 1.55M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.50 | -0.23 | - | 0.19 | -0.08 | -0.24 | -0.21 | -0.06 | -0.12 | -0.10 | 0.18 | -0.02 | -0.03 | -0.12 | - | -0.06 | -0.10 | -0.07 | 0.05 | 0.05 |
| R&D Expense | 1.56M | 1.27M | 1.71M | 1.54M | - | 6.46M | 1.44M | 3.42M | - | 6.27M | 1.61M | 2.83M | 886.00K | 1.99M | 2.68M | 1.62M | 690.00K | 744.00K | 535.00K | 1.12M | 615.00K | 651.00K | 2.97M | 505.00K | 1.16M | 3.71M | 1.11M | - | 1.88M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | 959.00K | 39.00K | - | 21.25M | 31.64M | 39.01M | 79.95M |
| Cost of Revenue | - | - | - | - | 6.93M | 10.58M | 15.60M | 37.21M |
| Gross Profit | - | 506.00K | -397.00K | - | 14.32M | 21.06M | 23.41M | 42.74M |
| Operating Expenses | - | - | - | - | 22.58M | 22.25M | 26.01M | 43.58M |
| Operating Income | -10.32M | -18.60M | -27.11M | - | -8.26M | -1.19M | -2.60M | -844.00K |
| EBITDA | - | - | - | - | -6.49M | -291.00K | -1.45M | 3.20M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -9.02M | -689.00K | -3.81M | -4.56M |
| Tax Provision | - | - | - | - | 0 | 247.00K | 15.00K | 43.00K |
| Net Income | -12.74M | -18.32M | -27.97M | - | -9.02M | -936.00K | -3.82M | -4.60M |
| Diluted EPS | - | - | - | - | -0.36 | -0.04 | -0.15 | -0.17 |
| R&D Expense | 5.63M | 11.55M | 14.10M | 6.24M | 4.00M | 3.32M | 3.25M | 7.76M |
Compounded Sales Growth
| 5 Years: | 55.53% |
| 1 Year: | 40.40% |
Compounded Profit Growth
| 5 Years: | 16.33% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +61.20% |
| 6 Months: | +87.04% |
| 3 Months: | +79.22% |
| 1 Month: | +29.13% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | 13.44M | 28.33M | 17.07M | 26.32M | - | 25.03M | 31.74M | 76.12M | 92.11M |
| Current Assets | - | - | - | - | - | 20.00M | 26.84M | 41.02M | 60.58M |
| Cash & Equivalents | 13.16M | 26.73M | 12.07M | 21.30M | - | 16.30M | 21.39M | 14.94M | 25.94M |
| Inventory | - | - | - | - | - | 557.00K | 911.00K | 15.23M | 15.42M |
| Receivables | - | - | - | - | - | 1.85M | 3.41M | 5.36M | 11.76M |
| Total Liabilities | 1.31M | 2.02M | 6.52M | 10.66M | - | 11.95M | 16.26M | 51.70M | 65.96M |
| Current Liabilities | 793.00K | 2.02M | 1.96M | 3.79M | - | 6.46M | 16.24M | 19.95M | 38.49M |
| Long Term Debt | - | - | - | - | 5.26M | 5.38M | - | 29.81M | 21.77M |
| Total Debt | - | - | - | - | - | 6.52M | 5.40M | 29.92M | 31.02M |
| Total Equity | -6.87M | 26.30M | 10.55M | 17.63M | - | 13.08M | 15.48M | 24.43M | 26.15M |
| Shares Outstanding | - | - | - | - | - | 25.35M | 25.69M | 26.71M | 27.05M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.14M | -18.03M | -22.35M | - | 4.82M | 6.82M | 969.00K | 10.52M |
| Investing Cash Flow | -236.00K | -1.85M | -50.00K | - | -2.79M | -775.00K | -40.01M | -333.00K |
| Financing Cash Flow | 21.96M | 5.20M | 31.62M | - | -134.00K | -957.00K | 32.59M | 815.00K |
| Capital Expenditure | -236.00K | -1.10M | -50.00K | - | -2.79M | -775.00K | -10.01M | -333.00K |
| Free Cash Flow | -8.38M | -19.12M | -22.40M | - | 2.03M | 6.04M | -9.04M | 10.19M |
| Net Change in Cash | - | - | - | - | 1.90M | 5.08M | -6.45M | 11.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | 52.8% | -1,017.9% | - | 67.4% | 66.6% | 60.0% | 53.5% |
| Operating Margin % | - | -1,939.6% | -69,515.4% | - | -38.9% | -3.8% | -6.7% | -1.1% |
| Net Margin % | - | -1,910.3% | -71,717.9% | - | -42.4% | -3.0% | -9.8% | -5.8% |
| ROE % | -48.4% | -173.6% | -158.7% | - | -69.0% | -6.0% | -15.7% | -17.6% |
| ROCE % | -39.2% | -123.1% | -120.4% | - | -44.5% | -7.7% | -4.6% | -1.6% |
Shareholding Pattern
Insiders
4.89%
Institutions
65.40%
Public Float
68.76%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Opaleye Management Inc. | 10.44% | 2.86M | $87.09M |
| 2 | EcoR1 Capital, LLC | 7.93% | 2.17M | $66.14M |
| 3 | Blackrock Inc. | 6.27% | 1.72M | $52.29M |
| 4 | Nantahala Capital Management, LLC | 4.29% | 1.18M | $35.81M |
| 5 | Vanguard Capital Management LLC | 3.63% | 994.09K | $30.27M |
| 6 | Geode Capital Management, LLC | 2.11% | 577.67K | $17.59M |
| 7 | State Street Corporation | 1.94% | 530.22K | $16.15M |
| 8 | National Philanthropic Trust | 1.80% | 492.11K | $14.98M |
| 9 | Morgan Stanley | 1.74% | 477.96K | $14.55M |
| 10 | Westside Investment Management, Inc. | 1.71% | 467.92K | $14.25M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ETON
No recent headlines available.